Nalo Ford
Psychiatric/Mental Health · Baltimore, MDNPI 1780265181
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $44.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$612
- Teva Pharmaceuticals USA, Inc.$611
- E.r. Squibb & Sons, L.L.C.$605
- Novo Nordisk$486
- AstraZeneca$475
- plus $4K from 22 others
What the payments were for
- Food & beverage$7,60498%
- Education$1412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $1,332 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $612 |
| Teva Pharmaceuticals USA, Inc. | 15 | $611 |
| E.r. Squibb & Sons, L.L.C. | 13 | $605 |
| Novo Nordisk | 4 | $486 |
| AstraZeneca(2 entities) | 4 | $475 |
| Neurocrine Biosciences, Inc. | 8 | $280 |
| Amgen(2 entities) | 2 | $266 |
| EMD Serono, Inc. | 2 | $255 |
| Sanofi-aventis U.S. LLC | 2 | $230 |
| Coloplast | 2 | $217 |
| Idorsia Pharmaceuticals US Inc | 2 | $211 |
| Aimmune Therapeutics, Inc. | 2 | $205 |
| Alkermes, Inc. | 5 | $200 |
| Sage Therapeutics, LLC | 2 | $198 |
| Biogen | 2 | $193 |
| Axsome Therapeutics, Inc. | 4 | $182 |
| Supernus Pharmaceuticals, Inc. | 4 | $161 |
| Boston Scientific | 1 | $138 |
| Indivior Inc. | 6 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $111 |
| Sanofi Pasteur Inc. | 1 | $107 |
| Vertos Medical, Inc. | 1 | $107 |
| Bayer | 1 | $107 |
| Vertex | 1 | $97 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| TMS Neurohealth Centers Inc. | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,746 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 16 | $22,743 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 34 | $2,457 |
| Guanfacine Hcl | 22 | $1,169 |
| Quetiapine Fumarate | 72 | $984 |
| Divalproex Sodium | 48 | $930 |
| Benztropine Mesylate | 51 | $667 |
| Aripiprazole | 16 | $628 |
| Olanzapine | 23 | $580 |
| Trazodone Hcl | 71 | $497 |
| Risperidone | 48 | $438 |
| Haloperidol | 32 | $412 |
| Gabapentin | 58 | $402 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $369 |
| Escitalopram Oxalate | 53 | $328 |
| Hydroxyzine Hcl | 16 | $306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,332 | $22,74316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Other psychiatric/mental health in Baltimore
- Olalekan AjayiBaltimore$10K
- Amy GrammasBaltimore$8K
- Digna Cespedes-CloudBaltimore$8K
- Gerald ChiaBaltimore$6K
- Chinwe OkudoBaltimore$6K
- Tamar RodneyBaltimore$6K
- Peter IgeBaltimore$5K
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.